352 related articles for article (PubMed ID: 7907246)
1. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. European Collaborative Study Group.
BMJ; 1994 Feb; 308(6926):437-40. PubMed ID: 7907246
[TBL] [Abstract][Full Text] [Related]
2. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
6. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
8. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.
Phair J; Muñoz A; Detels R; Kaslow R; Rinaldo C; Saah A
N Engl J Med; 1990 Jan; 322(3):161-5. PubMed ID: 1967190
[TBL] [Abstract][Full Text] [Related]
9. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
[TBL] [Abstract][Full Text] [Related]
10. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection.
Kovacs A; Frederick T; Church J; Eller A; Oxtoby M; Mascola L
JAMA; 1991 Apr; 265(13):1698-703. PubMed ID: 1672169
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
Eigenmann C; Flepp M; Bernasconi E; Schiffer V; Telenti A; Bucher H; Wagels T; Egger M; Furrer H;
Clin Infect Dis; 2003 Apr; 36(7):917-21. PubMed ID: 12652393
[TBL] [Abstract][Full Text] [Related]
13. Impact of pregnancy on maternal AIDS.
Kumar RM; Uduman SA; Khurrana AK
J Reprod Med; 1997 Jul; 42(7):429-34. PubMed ID: 9252934
[TBL] [Abstract][Full Text] [Related]
14. [Sputum examination in the diagnosis of Pneumocystis carinii pneumonia in HIV-infected patients].
Schlatter CE; Kuster H; Lüthy R; Weber R; Russi EW; Opravil M
Dtsch Med Wochenschr; 1994 Aug; 119(34-35):1151-5. PubMed ID: 8076502
[TBL] [Abstract][Full Text] [Related]
15. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children.
AIDS; 1999 May; 13(8):927-33. PubMed ID: 10371173
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis carinii infection among human immunodeficiency virus (HIV) infected Myanmar patients.
Kay-Thwe-Han ; Rai-Mra ; Htin-Aung-Saw ; Ye-Htut ; Wynn-Naing
Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):577-9. PubMed ID: 15115131
[TBL] [Abstract][Full Text] [Related]
17. Pneumocystis pneumonia among HIV patients in Malaysia.
Asmal HS; Mustafa M; Abdullah S; Zaidah AR; Nurhaslindawati AR; Sarimah A; Chan YY; Ravichandran M
Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1293-7. PubMed ID: 20578464
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis carinii pneumonia in infants infected with the human immunodeficiency virus with more than 450 CD4 T lymphocytes per cubic millimeter.
Leibovitz E; Rigaud M; Pollack H; Lawrence R; Chandwani S; Krasinski K; Borkowsky W
N Engl J Med; 1990 Aug; 323(8):531-3. PubMed ID: 1974030
[No Abstract] [Full Text] [Related]
19. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
[TBL] [Abstract][Full Text] [Related]
20. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
